J. Nicoll

发表

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

J. Kuriyan, C. Sawyers, R. Paquette, 2002, Cancer cell.

1 CBL , CBLB , TET 2 , ASXL 1 and IDH 1 / 2 Mutations and Additional Chromosomal Aberrations Constitute Molecular Events in Chronic Myelogenous Leukemia

A. Jankowska, M. McDevitt, C. O'keefe, 2011 .

Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development.

C. Sawyers, R. Paquette, N. Shah, 2006 .

The Most Common Dasatinib-Resistant BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia Are Sensitive to VX-680: Rationale for Early Combination Kinase Inhibitor Therapy.

C. Sawyers, R. Paquette, N. Shah, 2006 .

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Susan O'Brien, Jorge Cortes, John Nicoll, 2006, The New England journal of medicine.

Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.

C. Sawyers, R. Paquette, N. Shah, 2010, Leukemia research.

Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy.

C. Sawyers, F. Huang, R. Paquette, 2005 .

Impact of a peer-led, community-based parenting programme delivered at a national scale: an uncontrolled cohort design with benchmarking

C. Day, J. Nicoll, Joshua Harwood, 2022, BMC Public Health.

Dasatinib (BMS-354825) in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: Update of a Phase I Study.

Taosheng Chen, C. Sawyers, H. Kantarjian, 2005 .

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.

Christopher Weier, C. Sawyers, N. Shah, 2008, Cancer cell.

Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder

Aadel A. Chaudhuri, David Baltimore, Ryan M. O’Connell, 2008, The Journal of experimental medicine.

CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

Michael A McDevitt, Eric Hsi, John Nicoll, 2011, Blood.

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

C. Sawyers, R. V. van Etten, N. Shah, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.

C. Sawyers, H. Kantarjian, A. DeCillis, 2004 .

Sequential Kinase Inhibitor Therapy in CML Patients Can Select for Cells Harboring Compound BCR-ABL Kinase Domain Mutations with Increased Oncogenic Potency: Rationale for Early Combination Therapy of ABL Kinase Inhibitors.

C. Sawyers, R. Paquette, N. Shah, 2006 .

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

C. Sawyers, R. Paquette, N. Shah, 2007, The Journal of clinical investigation.

Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.

Gouri Nanjangud, David Elashoff, John Nicoll, 2011, Cancer genetics.

CBL , CBLB , TET 2 , ASXL 1 , and IDH 1 / 2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia

Michael A. McDevitt, Eric Hsi, John Nicoll, 2011 .

Targeted therapy for the treatment of imatinib‐resistant chronic myeloid leukemia: A pharmacogenetic analysis

C. Sawyers, N. Shah, J. Nicoll, 2005 .

A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML): Results from CA180002

C. Sawyers, H. Kantarjian, A. DeCillis, 2005 .

A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): Results from CA180002

C. Sawyers, H. Kantarjian, A. DeCillis, 2005 .

CBL, CBLB, TET2, ASXL1, and IDH1/2 Mutations as Well as Additional Chromosomal Aberrations Constitute Molecular Events Contributing to Malignant Progression In Advanced Philadelphia Chromosome-Positive Disorders.

A. Jankowska, M. McDevitt, J. Maciejewski, 2010 .

Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL)

C. Sawyers, H. Kantarjian, N. Donato, 2005 .

Clonal Hematopoiesis in Philadelphia Chromosome-Negative Bone Marrow Cells of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors

C. Sawyers, L. Gondek, R. Paquette, 2008 .